Back to top
more

Veracyte (VCYT)

(Delayed Data from NSDQ)

$43.43 USD

43.43
872,989

+0.24 (0.56%)

Updated Sep 1, 2026 04:00 PM ET

After-Market: $43.42 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (96 out of 248)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Bruker Stock May Benefit Following Its Investment in Ridom GmbH

by Zacks Equity Research

BRKR announces a new partnership with NGS bioinformatics solution provider Ridom GmbH.

Zacks Equity Research

Bruker Debuts Fourier 80 Multinuclear Benchtop FT-NMR: Stock to Gain?

by Zacks Equity Research

BRKR's latest innovation offers 1H NMR and a choice of 15 X-nuclei with just one click.

Zacks Equity Research

Veracyte (VCYT) Just Overtook the 20-Day Moving Average

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

Zacks Equity Research

Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength?

by Zacks Equity Research

Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Zacks Equity Research

Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

by Zacks Equity Research

BIO continues to attract investors' attention due to its robust performance in the ddPCR platform.

Zacks Equity Research

Is This the Right Time to Hold ALGN Stock in Your Portfolio?

by Zacks Equity Research

Align Technology continues to attract investors' confidence thanks to its share gains in the malocclusion market and strategic deals.

Zacks Equity Research

National Vision Stock Rises 28.2% YTD: Will the Rally Continue?

by Zacks Equity Research

EYE's strength in its largest brand and actions to achieve a healthier store fleet position the stock favorably.

Zacks Equity Research

Is Quest Diagnostics Stock Worth Holding Onto Right Now?

by Zacks Equity Research

Strong momentum in Advanced Diagnostics and strategic acquisitions continues to attract investors to DGX.

Zacks Equity Research

Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.